4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 65 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,251 | +4.4% | 2,612 | +48.2% | 0.00% | 0.0% |
| Q2 2023 | $31,839 | +5.1% | 1,762 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $30,289 | -34.7% | 1,762 | -15.6% | 0.00% | 0.0% |
| Q4 2022 | $46,352 | +176.3% | 2,087 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $16,779 | +15.2% | 2,087 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $14,567 | -53.8% | 2,087 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $31,555 | -82.6% | 2,087 | -74.8% | 0.00% | -50.0% |
| Q4 2021 | $181,751 | +11.6% | 8,284 | +37.2% | 0.00% | 0.0% |
| Q3 2021 | $162,818 | +25.8% | 6,037 | +102.3% | 0.00% | 0.0% |
| Q1 2021 | $129,446 | – | 2,984 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 3,000,000 | $38,190,000 | 4.02% |
| Casdin Capital, LLC | 1,033,811 | $13,160,414 | 1.46% |
| BVF INC/IL | 4,007,413 | $51,014,367 | 1.38% |
| Deep Track Capital, LP | 2,778,107 | $35,365,302 | 1.36% |
| Opaleye Management Inc. | 308,500 | $3,927,205 | 1.28% |
| Eagle Health Investments LP | 437,911 | $5,574,607 | 1.23% |
| Novo Holdings A/S | 1,200,000 | $15,276,000 | 1.13% |
| RA Capital Management | 4,163,211 | $52,997,676 | 1.04% |
| VIKING GLOBAL INVESTORS LP | 4,787,914 | $60,950,145 | 0.25% |
| HighVista Strategies LLC | 33,419 | $425,424 | 0.20% |